Mersana Therapeutics Inc
MRSN.O- Latest Trade
- trading higher8.56USD
- 0
- 0.00%
- As of Jun 8 2023. Values delayed up to 15 minutes
- Today's Range
- -- - --
- 52 Week Range
- 2.92 - 8.95
- Previous Close
- 8.56
- Open
- 0.00
- Volume
- 0.00
- 3 Month Average Trading Volume
- 39.98
- Shares Out (Mil)
- 114.39
- Market Cap
- 979.14
- Forward P/E
- -4.38
- Dividend Yield
- 0.00
Key Statistics
1.38 mean rating - 8 analysts
- P/E Excl. Extra Items (TTM)
- 0.00
- Price To Sales (TTM)
- 30.27
- Price To Book (Quarterly)
- 14.52
- Price To Cash Flow (Per Share TTM)
- 0.00
- Total Debt/Total Equity (Quarterly)
- 38.89
- Long Term Debt/Equity (Quarterly)
- 38.89
- Return On Investment (TTM)
- -102.81
- Return On Equity (TTM)
- -76.87
2021 (millions USD)
About Mersana Therapeutics Inc (MRSN.O)
Company Information
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need. The Company lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b and is being studied in UPLIFT, a single-arm registrational trial in patients with platinum-resistant ovarian cancer; UPGRADE-A, a Phase I clinical trial evaluating UpRi in combination with carboplatin, and UP-NEXT, a Phase III clinical trial of UpRi as monotherapy maintenance following treatment with platinum doublets in recurrent platinum-sensitive ovarian cancer. Its pipeline also includes XMT-1660, a Dolasynthen ADC targeting B7-H4 in a Phase I clinical trial, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2), in addition to other earlier-stage assets.
Address
840 Memorial DrCAMBRIDGE, MA
02139-3789
United States
Industry
Biotechnology & Drugs
Executive Leadership
- David M. Mott
- Independent Chairman of the Board
- Anna Protopapas
- President, Chief Executive Officer, Director
- Brian Deschuytner
- Chief Financial Officer, Senior Vice President
- Timothy B Lowinger
- Senior Vice President, Chief Science and Technology Officer
- Alejandra V. Carvajal
- Senior Vice President, Chief Legal Officer
- Tushar Misra
- Senior Vice President, Chief Manufacturing Officer
- Arvin Yang
- Senior Vice President, Chief Medical Officer
- Lawrence M. Alleva
- Independent Director
- Willard H. Dere
- Independent Director
- Allene M. Diaz
- Independent Director
- Andrew A. F. Hack
- Independent Director
- Kristen M. Hege
- Independent Director
- Martin H. Huber
- Independent Director
Latest News
- BusinessU.S. FDA places Mersana's cancer drug trial on hold following death
Mersana Therapeutics Inc said on Monday the U.S. drug regulator had placed on hold an early-stage trial testing its experimental cancer drug after the death of a participant.
Financials
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,964.60 | 0.05% |
| Copper | 727.00 | 0.28% |
| Brent Crude Oil | 76.12 | 0.21% |
| CBOT Soybeans | 1,368.50 | 0.39% |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 4,293.93 | -- |
| Euro STOXX 50 | 4,285.05 | 0.29% |
| FTSE 100 | 7,562.92 | 0.48% |
| Nikkei 225 | 32,265.17 | 1.97% |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes